Majella E. Lane
`School of Pharmacy
`Senior Lecturer, Director of the Skin Research Group
`October 1st 2008
`
`
`Curriculum Vitae
`
`
`
`1. Personal Details
`Name:
`Department:
`Present appointment:
`Date of appointment:
`
`
`
`
`Institution
`Trinity College, Dublin
`Trinity College, Dublin
`Trinity College, Dublin
`Trinity College, Dublin
`
`
`Institution
`Trinity College, Dublin
`Trinity College, Dublin
`Trinity College, Dublin
`School of Pharmacy, University of
`London
`School of Pharmacy, University
`College London
`School of Pharmacy, University
`College London
`
`
`
`2. Education/Qualifications
`Dates
`Detail of degree; diploma; other qualification
`1992
`B.Sc.
`1994
`Diploma in Statistics
`1995
`Diploma in Management
`1997
`Ph.D.
`
`
`
`3. Professional History (in chronological order)
`Dates
`Detail of position held
`01/10/1995
`Lecturer in Pharmaceutical Chemistry
`1/10/1997
`Lecturer in Pharmaceutics
`1/10/1998
`Director, M.Sc. Pharmaceutical Technology
`1/10/2005
`Lecturer in Pharmaceutics
`
`
`1/10/2008
`Senior Lecturer in Pharmaceutics
`
`
`1/10/2010
`Director, Skin Research Group
`
`4. Other Appointments and Affiliations
`
`Extra ordinary Professor in Pharmaceutical Sciences, Northwest University Potchefstroom
`South Africa
`
`Membership of Professional Bodies
` Member of the Royal Pharmaceutical Society of Great Britain (2000)
` Member of the Pharmaceutical Society of Ireland (1993)
`
`
`
`External Professional Activities
` Member of the Academy of Pharmaceutical Sciences of Great Britain
` Member of the American Association of Pharmaceutical Scientists
` Member of the Controlled Release Society
` Member of the European Federation for Pharmaceutical Sciences
` Member of the United Kingdom-Ireland Controlled Release Society
` Secretary and Member of the Skin Forum
` Member of the Bioactives Committee of the Society of the Chemical Industry
` Member of the Society of Cosmetic Scientists
`
`
`
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2187 - 1/21
`
`

`
`Participation in Research Networks and collaborations
`2002 to 2005 - Member of the FLUSAFE research network (Consortium of research institutes aimed
`at developing a European technology platform for improved Haemophilus influenza vaccine
`formulations. The consortium consisted of approximately 30 European research institutes)
`
`2009 and ongoing – Member of NOFPACC (Novel skin formulations for pain control in children) a
`group of EU researchers established under funding from Framework 7 to develop innovative
`formulations for delivery of analgesia via the skin.
`
`Currently I serve as the Chair of Skin Forum (www.skin-forum.eu) which is an interdisciplinary
`network of UK scientists who share a common interest in the structure and characterisation of
`human skin. The forum evolved originally from an EPSRC funded network and is recognised as one
`of the most influential networks in dermal and cosmetic research today. On behalf of Skin Forum, I
`have concluded successful negotiations with the Association de Pharmacie Galénique Industrielle
`(APGI, France) and Arbeitsgemeinschaft für pharmazeutische Verfahrenstechnik (APV, Germany)
`to run joint meetings in order to establish Skin Forum as a pan-European group. I have also served
`as programme and scientific chair for these conferences. In January 2006 I was invited to join the
`Bioactives Committee of the Society of the Chemical Industry (SCI) to develop links between Skin
`Forum and the SCI. This resulted in a very successful one day meeting and a further event took
`place in late 2012. I have chaired a number of sessions at the Controlled Release Society’s Annual
`Meetings, and presented my work at the American Association of Scientists Annual Meeting and the
`UKPharmSci conference.
`
`Consultancies
`Bioprogress Ltd., UK
`Futura Ltd., UK
`Gattefossé, France
`Glaxo Smith Kline, USA
`Maruho Ltd., Japan
`Mundipharma Ltd., UK
`Supportive Therapeutics, USA.
`
`Advisory Board Membership
`Academy of Pharmaceutical Sciences of Great Britain
`Skin Forum
`Stratum Corneum
`Technical Advisory Group, Skin Health in the Developing World. Bill & Melinda Gates Foundation.
`
`Associate Editor
`International Journal of Cosmetic Science
`
`Editorial Board Membership
`American Journal of Pharmaceutical Sciences
`Cosmetics
`Current Drug Delivery
`Drug Delivery Letters
`International Journal of Nanomaterials, Nanotechnology and Nanomedicine
`Journal of Biophysical Chemistry
`Journal of Drug Targeting
`Journal of Pharmaceutical Science
`International Journal of Pharmaceutics
`Phytotherapy Research
`
`
`
`Guest Editor
`International Journal of Pharmaceutics
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2187 - 2/21
`
`

`
`
`Scientific Reviewer activities
` AAPS PharmSciTech
` Advanced Drug Delivery Reviews
` Archives of Dermatological Research
` Biopharmaceutics and Drug Disposition
` BMC Infectious Diseases
` British Journal of Dermatology
` Burns
` Colloids and Surfaces A: Physicochemical and Engineering Aspects
` Colloids and Surfaces B: Biointerfaces
` Critical Reviews in Therapeutic Drug Carrier Systems
` Current Pharmaceutical Design
` Drug Delivery
` Drug Discovery Today
` Drugs
` European Journal of Pharmaceutics and Biopharmaceutics
` European Journal of Pharmaceutical Sciences
` Expert Opinion on Drug Metabolism and Toxicology
`International Journal of Nanomedicine
`
`
`International Journal of Pharmaceutics
`
`International Journal of Pharmacy Practice
` Journal of Applied Polymer Science
` Journal of Controlled Release
` Journal of Drug Delivery, Science and Technology
` Journal of Drug Targeting
` Journal of Investigative Dermatology
` Journal of Liposome Research
` Journal of Materials Chemistry
` Journal of Microencapsulation
` Journal of Molecular Liquids
` Journal of Pharmaceutical Sciences
` Journal of Pharmacy and Pharmacology
` Journal of Photochemistry and Photobiology B: Biology
` Methods
` Molecular Pharmaceutics
` Pharmaceutical Research
` Physical Chemistry Chemical Physics
` Phytotherapy Research
` Postgraduate Medicine
` Polymer Testing
` Science and Justice
` Scientific Reports
` Skin Pharmacology and Physiology
` Therapeutic Delivery
` Veterinary Anaesthesia and Analgesia
`
`
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2187 - 3/21
`
`

`
`Peer Review activities for Government Research Organisations
`National Research Foundation, South Africa
`Act as a reviewer for the South Africa National Research Foundation (NRF) and regularly asked to
`evaluate the quality of the research outputs of South African academic staff. Researchers at South
`African higher education and some other research institutions apply to the NRF for evaluation and
`rating on the basis of the opinions of national and international peers about their research outputs
`and contribution over the preceding seven years. A rated researcher has access to research funding
`and is able to use the rating as a benchmark for personal development and career advancement.
`
`EPSRC, UK
`Member of the EPSRC College and frequently asked to review grant applications and end-of-grant
`reports for this body.
`
`MRC, UK
`Act as a reviewer for research grant applications.
`
`BBSRC, UK
`Act as a reviewer for research grant applications.
`
`Irish Research Council for Science, Engineering and Technology, Ireland
`Act as a reviewer for research grant applications and assessor for postgraduate and postdoctoral
`fellowship funding.
`
`National Institutes for Health, USA
`Reviewer (Research Grants and Academic Research Enhancement Awards)
`
`National Medical Research Council, Singapore
`Act as a reviewer for research grant applications.
`
`
`
`Other positions
`Editor, Irish Pharmaceutical Union Review (1995 – 2005)
`
`Visiting Assistant Scientist at the Department of Pharmaceutical Sciences, College of Pharmacy,
`University of Michigan, Ann Arbor, Michigan, USA.
`
`
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2187 - 4/21
`
`

`
`Awarding/electing body
`Trinity College, Dublin
`
`Trinity College, Dublin
`
`Janssen Ltd, Belgium
`
`Glaxo Smith Kline, Ireland
`
`Eolas, Ireland
`
`European Federation for
`Pharmaceutical Sciences
`
`American Association of
`Pharmaceutical Scientists
`
`Mendell Ltd.
`
`
`
`Skin Forum, UK.
`
`
`
`
`
`5. Prizes, Awards and other Honours:
`Dates
`Detail of prize, award or honour
`1990
`Foundation Scholarship
`
`
`1992
`University Gold medal
`
`
`1992
`Janssen Medal
`
`
`1992
`Wellcome Medal
`
`
`1992
`EOLAS Basic Research Award
`
`
`1994
`Best poster award
`
`
`
`
`
`1997
`
`Best poster award
`
`
`
`Mendell Award, 17th Pharmaceutical
`Technology Conference, Dublin
`
`Best paper, Best poster (Graduate awards)
`
`
`
`1998
`
`
`
`2007
`
`
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2187 - 5/21
`
`

`
`6. Grants:
`Elan Pharma (Ireland) PI. IR Pounds 120,000 (1998)
`Provost’s Academic Development Fund, Trinity College, Dublin. PI. IR Pounds 32,000 (1999)
`Rice Steele Ltd (Ireland). PI. IR Pounds 75,000 (2000)
`Fulbright Travel Award Ireland – USA. IR Pounds 16,000 (2002)
`EPSRC EP/D50273X/1 Co I. £180,049 (2005)
`Maruho Ltd. (Japan). PI. GB £ 112,000 (2006)
`EPSRC Doctoral Training Award. CoI. £65,000 (2007)
`Portuguese Science Foundation – FCT. PI. £83,400 (2007)
`Acrux Ltd. (Australia). PI. £86,500 (2007)
`International Islamic University Malyasia. PI. £42,000 (2008)
`Procter & Gamble, UK. PI. £92,000 (2008)
`Croda Ltd., U.K. PI. £105,000 (2009)
`Glaxo Smith Kline, UK PI. £85,000 (2009)
`ISP Ltd., USA. PI. £88,000 (2009).
`Higher Education Ministry, Syria. PI. £56,000 (2009).
`Shiseido Ltd., Japan. PI. £106,000 (2009)
`Bloomsbury Studentship, Bloomsbury Colleges. UK PI. £52,000 (2009)
`British Council Scholarship. PI. £103,000 (2010)
`Dermal Ltd. UK. PI. £84,600. (2010)
`Procter & Gamble, UK. PI. £97,600. (2011)
`Higher Education Department. Iraq. PI. £88,000 (2011)
`Dermal Ltd. UK. PI. £12,500. (2011)
`Higher Education Ministry, Malaysia PI. £62,000 (2012)
`DSM Ltd. Switzerland PI. £46,000 (2012)
`Dermal Ltd. UK PI. £12,500 (2012)
`Gojo Ltd. USA PI. £46,000 (2013)
`Glaxo Smith Kline USA PI. £109,000 (2013)
`EPSRC Doctoral Training Award UK PI. £109,000 (2013)
`Phospholipid Research Institute £19,000 (2014)
`EPSRC Case Award PI. £120,000 (2015)
`DSM Ltd. Switzerland PI. £75,000 (2015)
`
`PI = Principal Investigator; Co I = Co-investigator
`
`
`
`The reputation of the laboratory has attracted graduate students and PDRAs with fellowship funding
`from their home governments and institutions (including Egypt, India, Iran, Iraq, Japan, Malaysia,
`Pakistan, Portugal, South Africa, Spain, and Syria).
`
`
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2187 - 6/21
`
`

`
`7. Invited talks:
`Date
`Details
`
`
`1998
`European Federation of Pharmaceutical Sciences Annual Meeting, Milan, Italy
`17th Pharmaceutical Technology Conference, Dublin, Ireland.
`1998
`1998
`Elan Pharma, Dublin, Ireland
`12th International Symposium on Microencapsulation, London, U.K.
`1999
`2000
`Controlled Release Society: Novel Vaccine Formulations, Dublin, Ireland
`2000
`American Association of Pharmaceutical Scientists Annual Meeting, Texas, USA.
`2002
`American Association of Pharmaceutical Scientists Annual Meeting, Toronto, USA
`2003
`Department of Pharmaceutical Sciences, University of Michigan, USA
`14th International Symposium on Microencapsulation, Singapore
`2003
`1st European Conference Drug Delivery &Pharmaceutical Technology, Seville, Spain
`2004
`2004
`PharmSci Fair, Nice, France
`2005
`Wyeth Pharma, Havant U.K.
`15th International Symposium on Microencapsulation, Parma, Italy
`2005
`2005
`United Kingdom-Ireland Controlled Release Annual Meeting, Loughborough, UK
`2006
`Society of the Chemical Industry, London, UK
`2006
`North West University, Potchefstroom, South Africa
`2006
`Chulongkorn University, Thailand
`2006
`Department of Pharmaceutical Technology, Parma, Italy
`2007
`DTL Ltd. UK
`2007
`Universidad Nacional de Quilmes, Buenos Aires, Argentina
`2008
`University of Tromso, Norway
`2008
`Maruho Ltd., Kyoto, Japan
`2009
`Teikoku Pharma, Sanbonmatsu, Japan
`2009
`Josei University, Japan
`2010
`Swedish Academy of Pharmaceutical Sciences, Stockholm, Sweden
`2010
`University of Helsinki, Finland
`2010
`Faculty of Chemical and Pharmaceutical Science, University of Chile
`2011
`Lohmann Therapie-Systeme, Andernach, Germany
`2011
`Division of Chemistry, Sheffield Hallam University
`2011
`Society of Cosmetic Chemists, London, UK
`2011
`Controlled Release Society Annual Symposium, National Harbor, USA
`2011
`UK PharmSci, Nottingham, UK
`2011
`Glaxo Smith Kline, UK
`2012
`Stiefel, USA
`2012
`University of North Carolina, Chapel Hill, USA
`2012
`International Conference and Workshop on Biological Barriers, Saarland, Germany
`2012
`The anti-aging skin care conference, London UK
`2012
`Society of the Chemical Industry, London, UK
`2012
`Oriflame, Ireland
`2013
`PQRI, Washington, USA
`2013
`Cranfield University, UK
`2013
`Skin Forum, UK
`2013
`University of Vienna, Austria
`2013
`Reckitt Benckiser, UK
`2013
`Syngenta, UK
`2013
`UKPharmSci, Edinburgh, UK
`2013
`Phospholipid Research Centre, Heidelberg, Germany
`2013
`SCS Formulate, UK
`2013
`Avon, USA
`2014
`Almirall, Barcelona, Spain
`2014
`Biospain, Santiago de Compostela, Spain
`2014
`Phospholipid Research Centre, Braunschweig, Germany
`2014
`IRDG Meeting, Astra Zeneca, UK
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2187 - 7/21
`
`

`
`2014
`2014
`2015
`2015
`2015
`2015
`2015
`2015
`2016
`
`3rd Intl. Conference on Nutraceutical & Pharmaceutical Sciences, Tokyo, Japan
`Gattefossé, St Priest, France
`University of Coleraine
`Interpharm, Chester, UK
`Gordon Research Conference, Waterville Valley, USA
`IFSCC, Zurich, Switzerland
`SCS Formulate, Coventry, UK
`Reckitt Benckiser, UK
`Brazilian Cosmetic Society, Sao Paulo
`
`
`
`8. Academic supervision:
`Date
`Details
`PhD
`
`Fiona Sheena Brennan (1st Supervisor)
`2002
`Karl Alexander Levis (1st Supervisor)
`2003
`Mark Hanlon (1st Supervisor)
`2004
`2006
`Xue Li (Joint Supervisor)
`2008
`Paulo Santos (Joint Supervisor)
`2008
`Nisar Shah (Joint Supervisor)
`2009
`Murtaza Tambuwala (Joint Supervisor)
`Gabriela Oliveira (1st Supervisor)
`2010
`Sonal Chavda (1st Supervisor)
`2011
`Kazumasa Hirata (1st Supervisor)
`2011
`Diar Mohammed (1st Supervisor)
`2012
`Hazrina Ab-Hadi (1st Supervisor)
`2012
`Mihaela Gorcea (1st Supervisor)
`2012
`Rita Isabel Henrique Neves Vieira (1st Supervisor)
`2013
`Marta Machado (1st Supervisor)
`2013
`Rita Mateus (1st Supervisor)
`2014
`Haydar M. Abdalghafor (1st Supervisor)
`2014
`Fouad Helal (1st Supervisor)
`2014
`Tasnuva Haque (1st Supervisor)
`2015
`Anna Duzynska (1st Supervisor)
`2015
`Mohammed Sattar (1st Supervisor)
`2015
`
`Students currently completing their PhD
`1st Supervisor
`Choon Fu, Goh
`
`1st Supervisor
`Parisi, Nicola
`
`1st Supervisor
`Patel, Avnish
`
`1st Supervisor
`Raj, Nidhin
`
`
`1st Supervisor
`Rowling, Lin
`
`1st Superviso
`Brand, Nicolas
`
`1st Supervisor
`Paz, Miguell
`
`
`
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2187 - 8/21
`
`

`
`MSc. in Pharmaceutical Technology
`Trinity College, Dublin 2000 (1st Supervisor)
`McBride, Bryan
`
`Trinity College, Dublin 2001 (1st Supervisor)
`Farrell, Lisa
`
`Manning, Robert Emmet Trinity College, Dublin 2001(1st Supervisor)
`Walsh, Patricia Geraldine Trinity College, Dublin 2001(1st Supervisor)
`Trinity College, Dublin 2001(1st Supervisor)
`Whelan, Deirdre Ann
`Trinity College, Dublin 2003 (1st Supervisor)
`Nghiem, Xuan-Tien
`Trinity College, Dublin 2004 (1st Supervisor)
`Tambuwala, Murtaza
`Trinity College, Dublin 2004 (1st Supervisor)
`Coppins, Jennifer P.
`Trinity College, Dublin 2005 (1st Supervisor)
`McCormack, Yvonne
`Trinity College, Dublin 2005 (1st Supervisor)
`Kieran, Aisling
`
`Trinity College, Dublin 2005 (1st Supervisor)
`McGrath, Caoimhe
`Trinity College, Dublin 2005 (1st Supervisor)
`Amezua, Patricia
`
`Trinity College, Dublin 2005 (1st Supervisor)
`Hughes, Robert
`
`
`MSc. In Drug Delivery
`Ahlan, Mohammed
`Ogawa, Chinedu
`
`Gambar, Garima
`
`Desai, Shefali
`
`Ab-Hadi, Hazrina
`
`Zhang, Ying
`
`Abghalfor, Haydar
`
`Purohit, Pallavi
`
`Tewi, Shweta
`
`Madaan, Shivam
`
`
`M.Res.
`Rowling, Lin
`
`
`University of London, 2006 (1st Supervisor)
`University of London, 2006 (1st Supervisor)
`University of London, 2008 (1st Supervisor)
`University of London, 2008 (1st Supervisor)
`University of London, 2008 (1st Supervisor)
`University of London, 2009 (1st Supervisor)
`University of London,.2009 (1st Supervisor)
`University of London, 2011 (1st Supervisor)
`University of London, 2011 (1st Supervisor)
`University of London, 2011 (1st Supervisor)
`
`University of London, 2012 (1st Supervisor)
`
`
`
`
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2187 - 9/21
`
`

`
`
`9. Research career activity:
`My research philosophy can be expressed as “To understand and characterise the transport of
`actives and excipients across membranes to enable the improved design of pharmaceutical,
`cosmetic and veterinary formulations.” Principally this has been achieved by my expertise in the
`area of in vitro and in vivo models of the biological membranes which are the major barriers to drug
`delivery. The areas of activity may be broken down as follows:
`
`
`1. Establishment of in vitro and in vivo models of the nail, skin, buccal epithelium and to a lesser
`extent, the small intestine, for the study of drug transport. I have identified human tissue
`sources within the UK and externally. Full National Health Service ethical approval for
`storage and use of such tissue has been awarded. Validated models for skin and buccal
`transport have been established. I frequently host visiting scientists from the EU and Asia
`who wish to develop expertise in these models. This has also allowed participation in EU
`networks with collaborators who recognise my group as a centre of excellence for membrane
`transport studies.
`
`
`2. Characterisation of biological membranes. Model membranes and human nails and skin are
`characterised by the research group using a range of techniques, principally Franz cell
`diffusion experiments, Attenuated Total Reflectance
`Infra Red Spectroscopy, Trans
`Epidermal Water Loss (TEWL) and impedance measurements. Knowledge of the barrier
`function of the membrane permits an understanding of how materials permeate and will
`indicate whether the partition or diffusion behaviour of the material dominates its transport
`characteristics. More recently we have begun to utilise Confocal Raman spectroscopy to
`probe the influence of excipients on drug disposition in skin in humans in vivo.
`
`3. In addition to the biophysical tools which we currently use to assess skin barrier function, the
`activity of proteases responsible for skin desquamation may potentially be a useful marker of
`skin competence. To this end I have developed and validated novel assays for the
`measurement of epidermal turnover in tape strips of human skin. The long-term goal will be
`to identify markers which advance our understanding of why patient response to topical
`treatments and therapeutic interventions varies markedly across the population. The MRC
`has recently announced a call in the area of Stratified medicine and I have submitted an
`outline proposal, based on further refinement and exploitation of such markers of skin health,
`in collaboration with Professor Weller (Dermatology Department, University of Edinburgh).
`
`4. In collaboration with Professor Mohammed Ghavami and Dr Perry Xiao of London South
`Bank University, I propose to develop the in vivo measurement capability of the technique of
`Opto-Thermal Transient Emission Radiometry (OTTER) and Ultra Wide Band (UWB)
`processing. These techniques are fast, non-contacting, non-destructive and insensitive to
`small movements. The initial aims are to validate UWB measurements of healthy skin along
`with OTTER, and a longer term objective is to investigate the applications of UWB in the
`diagnosis of skin diseases. A grant application is currently in preparation for this work
`programme which will shortly be submitted to the EPSRC.
`
`
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2187 - 10/21
`
`

`
`10. Teaching career summary / activity
`I am responsible for two undergraduate courses:
`
`Course B – Manufacturing of Pharmaceutical Preparations
`
`Course F – Overcoming Biological Barriers
`
` I
`
`
`
` teach all years of the MPharm. Programme and the breakdown of my teaching is as follows:
`
` Course B 2 lectures, 2 tutorials Contact Hours 6
` Course C 5 lectures, 3 practicals Contact Hours 14
` Course E 6 lectures, 1 tutorial Contact Hours 8
` Course F 4 lectures, 1 tutorial Contact Hours 15 (Overcoming Biological Barriers)
` Course F Undergraduate research projects
` Course G Development of Final year therapeutic Wiki project with Dr. David West
` Foundation Degree 1 lecture Contact Hours 3
`
` I
`
` am currently undertaking a complete restructuring of the Overcoming Biological Barriers module and
`new topics will include biosensor devices, stem cell therapies and image guided drug therapy.
`
` I
`
` deliver teaching for the M.Sc. in Drug Delivery jointly with Course F. In addition I supervise a
`minimum of 2 M.Sc. students for a six month laboratory project each year. Because of the popularity
`of my research with the M.Sc. students, places in my group are often over-subscribed.
`
`
`
`11. Knowledge Transfer / Exchange activity
`I am regularly consulted by pharmaceutical companies who wish to design and deliver novel
`therapeutic entities via the skin and more recently, to and through buccal tissue. Because of my
`reputation in these areas, Acrux Ltd. (Australia), Procter & Gamble, ISP USA, Diomed UK, Unilever
`and Croda UK have supported a number of PhD studentships under my direction. I also act or have
`acted as a consultant for Acacia Pharma, York Pharma Ltd., Meldex Ltd, Liz Earle Skincare Ltd.,
`RiceSteele Ltd, Smith & Nephew Ltd., and Neurocure Ltd. (Ireland).
`
`12. Enabling activity (academic staff)
`2006 - 2011 External examiner for the M.Sc. in Drug Delivery and the M.Sc. in Drug Design taught
`programmes at Aston University.
`External examiner for PhD and MSc theses at the University of Aston, the School of Pharmacy,
`Queens University of Belfast, the Veterinary Sciences Division, Queens University of Belfast, School
`of Pharmacy, Royal College of Surgeons in Ireland, North West University, South Africa and the
`University of Hull, UK.
`
`
`
`13. Administration
` Tutee for undergraduate students
` Pharmaceutics Representative – Higher Degrees Committee, School of Pharmacy
` Academic Staff Representative – Joint Staff Negotiating Committee, School of Pharmacy
`
`
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2187 - 11/21
`
`

`
`14. Five most significant publications (or other forms of original output) in the last five years.
`
`Influence of Aqueous Cream BP on corneocyte size, maturity, skin protease activity, protein
`content and transepidermal water loss.
`Mohammed D, Matts PJ, Hadgraft J, Lane ME.
`Br J Dermatol. 2011 Jun;164(6):1304-10.
`*Together with papers from the groups of Prof. Richard Guy (University of Bath), Prof. Michael Cork
`(Sheffield University), this publication has resulted in a reclassification of the use of this product as a
`soap substitute in the British National Formulary.
`
`Depth profiling of stratum corneum biophysical and molecular properties.
`Mohammed D, Matts PJ, Hadgraft J, Lane ME.
`Br J Dermatol. 2011 May;164(5):957-65.
`*Development and validation of self-consistent set of metrics to probe skin barrier function and
`epidermal turnover.
`
`Nanoparticles and the skin-applications and limitations.
`Lane ME.
`J Microencapsul. 2011;28(8):709-16.
`*Despite much controversy the overall findings from the published literature discussed in this review
`confirm that nanoparticles are unlikely to penetrate the skin to any great depth.
`
`
`Formulation issues associated with transdermal fentanyl delivery.
`Santos P, Watkinson AC, Hadgraft J, Lane ME.
`Int J Pharm. 2011 Sep 15;416(1):155-9.
`*Fentanyl in transdermal patch form is the best selling transdermal formulation developed to date.
`This publication outlines the development of a novel transdermal spray formulation with comparable
`skin permeation to commercially available patches.
`
`
`
`Opto-Thermal Transient Emission Radiometry (OTTER) to image diffusion in nails in vivo.
`Xiao P, Zheng X, Imhof RE, Hirata K, McAuley WJ, Mateus R, Hadgraft J, Lane ME.
`Int J Pharm. 2011 Mar 15;406(1-2):111-3.
`*First report of the application of this technique to probe solvent diffusion in the nail.
`
`
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2187 - 12/21
`
`

`
`Book
`
` Rathbone, M. J., Hadgraft, J., Roberts, M. S., Lane, M.E. (Eds.) (2008). Modified
`Release Drug Delivery Technology. (2nd ed.). USA: Informa Healthcare.
`
`Book Chapters
`
` Shah VP, Yacobi A, Lane ME. (2015) Bioequivalence, Quality, and Novel
`Assessment Technologies for Topical Products: Current Challenges and Future
`Prospects. In: Topical Drug Bioavailability: Bioequivalence and Penetration, 2ND
`Edition (Editors V.P. Shah, H.I. Maibach, J. Jenner). Springer. Pages 389-398.
` Xiao P, Abdalghafor H, Lane ME (2014) Membrane solvent penetration
`measurements using contact imaging. In: Advances in Dermatological Sciences.
`Volume 1. Pp. 355-360. Royal Society of Chemistry, London.
` Lane ME. (2012). Emollients and skin barrier function. In Loden, M., Maibach, H. I.
`(Eds.). Treatment of Dry Skin Syndrome. The Art and Science of Moisturizers. (pp.
`513-524): Springer Heidelberg Dordrecht London.
` Nair AB, Hui X, Lane ME, Murthy SN. (2013) In vitro and in vivo models to evaluate
`topical nail formulations. In:Murthy, S.N., Maibach, H.I. (Eds.). Topical Nail Products
`and Ungual Drug Delivery. Pp. 123-148. CRC Press. Boca Raton, FL, USA.
` Lane ME, Hadgraft J. (2012). Skin permeation assessment: spectroscopic
`methods. In Benson, H. A. E., Watkinson, A. C. (Eds.). Topical and transdermal drug
`delivery: principles and practice (pp.155-166). New York: Wiley.
` Lane ME, Santos P, Watkinson AC, Hadgraft J. (2012). Passive skin permeation
`enhancement. In Benson, H. A. E., Watkinson, A. C. (Eds.). Topical and transdermal
`drug delivery: principles and practice (pp.23-42). New York: Wiley.
` Lane ME, Uchegbu IF, Schatzlein AG. (2010). Nanomedicines from Polymeric
`Amphiphiles. In Torchilin, V., Amiji, M. M. (Eds.). Handbook of materials for
`nanoscience (Vol. 1 pp.495-514). Singapore: Pan Stanford Publishing Pte. Ltd.
` Cork MJ, Moustafa M, Danby S, Vasilopoulos Y, Tazi-Ahnini R, Ward SJ, Hadgraft,
`J, Lane ME, Guy RH. (2009). Skin barrier function in atopic dermatitis. In Rawlings,
`A. V., Leyden, J. J. (Eds.). Skin Moisturization (2nd ed. pp.1-492). New York:
`Informa Healthcare.
` Wiechers JW, Judefeind A, du Plessis J, Kelly CL, Lane ME, Hadgraft J. (2008).
`The effect of changing the polarity of the stratum corneum on the dermal and
`transdermal delivery of cosmetically active ingredients. In: Wiechers, J. W.
`(Ed.). Science and application of skin delivery systems (pp.1-552). USA: Allured
`Publishing.
` Lane ME, Hadgraft J. (2007). In vitro – in vivo correlations in transdermal drug
`delivery. In Walters, K. A., Roberts, M. S. (Eds.). Dermal Absorption and Toxicity
`Assessment (2nd ed. ed. pp.1-600). USA: Informa Healthcare.
` Lane ME, Okumu FW, Balausubramanian P. (2007). Editor of: Injections and
`implants.
`In Lane, M.E., Rathbone, M. J., Roberts, M. S., Hadgraft, J.
`(Eds.). Modified Release Drug Delivery Technology (2nd ed. ed. Vol. 184 pp.123-
`132). USA: Informa Healthcare.
` Lane ME, Hadgraft J. (2013) Penetration enhancers solvents and the skin. In: Fahr,
`A, Douromis, D. (Eds). Drug delivery strategies for poorly soluble drugs. Wiley, New
`York. 359-371.
`
`
`
`1
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2187 - 13/21
`
`

`
` Lane ME, Watkinson AC, Hadgraft J. Editor of: Dermal and Transdermal Drug
`Delivery.
`In Lane, M.E., Roberts, M. S., Rathbone, M. J., Hadgraft, J.
`(Eds.). Modified Release Drug Delivery Technology (2nd ed. ed. Vol. 184 pp.263-
`272). Informa Healthcare.
`
`
`
`Conference Presentations
`
` Machado M, Hadgraft J. Lane ME. (2010). A new model for in vitro finite dose
`permeation studies. Journal of Pharmacy and Pharmacology. Wiley. (Vol. 62 pp.
`1240-1240). Wiley.
` Ab Hadi, H., Hadgraft, J., Lane, M.E. (2010). Chemical permeation enhancement
`strategies
`for
`improved
`topical
`caffeine
`delivery.
`Journal of Pharmacy and Pharmacology. (Vol. 62 pp. 1254-1255). Wiley.
` Lane ME, Mader KT, Hadgraft J, Kazarian SG, Tetteh J, McAuley WJ, Andanson
`JM. (2010). Investigation of skin permeation using ATR-FTIR spectroscopic imaging
`and multivariate target factor analysis. Journal of Pharmacy and Pharmacology (Vol.
`62 pp. 1279-1280). Wiley.
` Lane ME, Chavda SJ, Hadgraft J. (2010). Membrane investigations using
`biophysical methods and multivariate target factor analysis. Journal of Pharmacy and
`Pharmacology. (Vol. 62 pp. 1285-1286). Wiley.
` Lane ME, Mohammed D, Hadgraft J. (2010). Metrology of the stratum corneum.
`Journal of Pharmacy and Pharmacology. (Vol. 62 pp.1286-1287). Wiley.
` Lane ME, Vieira R., Anissimov Y, Watkinson AC, Hadgraft J. (2010). Modelling of
`drug permeation in human skin in vitro from finite dose applications. Journal of
`Pharmacy and Pharmacology. (Vol. 62 pp. 1287-1288). Wiley.
` Lane ME, Hadgraft J. Skin: a tortuous problem. (2007). International Journal of
`Cosmetic Science. (Vol. 29 pp. 224-224. Wiley.
` Lane ME, McAuley WJ, Santos P, Hadgraft J. (2006). Determination of the diffusion
`coefficient of cyanophenol in Carbosil membrane using ATR-FTIR spectroscopy.
`Journal of Pharmacy and Pharmacology (Vol. 58 pp. A47-A47). Wiley.
` Lane ME, Corrigan OI, Levis KA. (2004). Ketoprofen-induced permeability changes
`in the perfused rat intestine. AAPS Journal. (Vol. 6 pp. W4282-W4282). Springer.
` Lane ME, Corrigan OI, Levis KA. (2004) Comparison of two methods for
`assessment of drug-induced permeability changes. European Journal of
`Pharmaceutical Sciences. (Vol. 23 pp.52-52). Elsevier
` Lane ME, Corrigan OI, Levis KA. (2004). Pharmacokinetics of amino acid
`derivatives of ibuprofen in the rat. European Journal of Pharmaceutical Sciences.
`(Vol. 23 pp.70-71). Elsevier.
` Lane ME, Corrigan OI., Levis KA. (2004). Effect of ibuprofen on the rat
`intestinal permeability of GlySar. European Journal of Pharmaceutical Sciences.
`Elsevier. (Vol. 23 pp. 75-75. Elsevier.
` Lane ME, Corrigan OI, Amidon GL, Deasy PB, Landowski CP, Quigley JM. (2004).
`Synthesis and characterization of arginine derivatives of ibuprofen. AAPS Journal.
`(Vol. 6 pp. T2290-T2290) Springer.
` Lane ME, Corrigan OI, Levis KA. (2003). Dependence of ibuprofen absorption on
`net intestinal fluid flux in the rat gut. AAPS Pharm Sci. (Vol. 5 pp. R6081-R6081)
`Springer.
`
`2
`
`
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2187 - 14/21
`
`

`
` Lane ME, Byrne RS, Deasy PB. The use of pororus aluminosilicate pellets
`produced by cryopelletization for sustained drug delivery. AAPS Pharm Sci. (Vol. 5
`pp. W5096-W5096. 2003
` Lane ME, Corrigan OI, Hanlon M, Levis KA, Gilmer JF. (2002). Synthesis and
`characterisation of arginine derivatives of non-steroidal anti-inflammatory drugs
`AAPS Pharm Sci. (Vol. 4 pp. R6124-R6124). Springer.
` Lane ME, Corrigan OI, O'Driscoll CM, Meaney CM, Gubbins RH. (1998).
`Correlation between permeability co-efficients in a perfused rat model and the CaCo-
`2 cell model. European Journal of Pharmaceutical Sciences. (Vol. 6 pp.24-24).
`Elsevier.
` Lane ME, Corrigan OI, O’Driscoll CM. (1998). Calculation of fractions of insulin
`absorbed and degraded in a perfused rat intestinal model. European Journal of
`Pharmaceutical Sciences. (Vol. 6 pp. 96-96) Elsevier.
` Lane ME, Corrigan OI, O’Driscoll CM. (1998). Effects of protease inhibitors on
`insulin stability and absorption in the rat intestine. 4th EUFEPS Congress, Milan,
`1taly, 11 European Journal of Pharmaceutical Sciences. (Vol. 6 pp. 97-97) Elsevier.
` Lane ME, Corrigan OI, O'Driscoll CM. (1998). The effects of bile salt fatty acid
`mixed micellar systems on insulin stability and absorption in the rat intestine. 17th
`Pharmaceutical Technology Conference. (Vol. 1 pp.109-120).
` Lane ME, Corrigan OI, O'Driscoll CM. (1994). The relationship between molecular
`size and gastrointestinal permeability. European Journal of Pharmaceuti